A Study of Ifinatamab Deruxtecan for Relapsed Small Cell Lung Cancer
This study is testing a drug called Ifinatamab deruxtecan (I-DXd) for people with small cell lung cancer (SCLC) that has come back (relapsed). It compares I-DXd to treatments your doctor might typically choose, such as Topotecan, Amrubicin, or Lurbinectedin. The main goals are to see if I-DXd can shrink tumors (objective response rate) and help people live longer (overall survival) over about 5 years. Adults aged 18 and older can join. The study is currently unclear on its status and plans to enroll 540 participants.
- Study design
- This interventional study plans to enroll 540 participants. It compares Ifinatamab deruxtecan to other standard treatments for relapsed small cell lung cancer.
- What's involved
- You would receive Ifinatamab deruxtecan intravenously (into a vein) on Day 1 of each 21-day cycle, or one of the standard treatments as decided by your doctor. Your tumor response and survival will be measured for up to approximately 5 years.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed from the date of randomization to the date of death due to any cause, up to approximately 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
At a glance
Conditions
Where it's being run
229 sites across 40 statesStudy leadership
- Global Clinical Director · STUDY_DIRECTOR · Daiichi Sankyo
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Overall Survival (OS)From the date of randomization to the date of death due to any cause, up to approximately 3.7 years
OS is defined as the time interval from the date of randomization to the date of death due to any cause.